Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Psyence Biomedical ( (PBM) ) just unveiled an announcement.
On June 18, 2025, Psyence Biomedical announced that its Chief of Global Impact, Mary-Elizabeth Gifford, was a featured speaker at the Psychedelic Science 2025 conference in Denver. The event, which took place from June 16-20, 2025, brought together industry leaders to discuss the future of psychedelic research and its commercial landscape. Psyence BioMed’s participation highlights its commitment to ethical business practices and its role in shaping the psychedelic medicine sector, emphasizing collaboration and accountability for both patient care and shareholder value.
More about Psyence Biomedical
Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. It is the first company focused on developing nature-derived psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. Psyence is dedicated to addressing unmet mental health needs, particularly in palliative care, using an evidence-based approach to develop safe and effective FDA-approved treatments.
Average Trading Volume: 96,758
Technical Sentiment Signal: Sell
Current Market Cap: $2.95M
For a thorough assessment of PBM stock, go to TipRanks’ Stock Analysis page.